13D Filing: RA Capital Management and Wave Life Sciences Ltd (WVE)

Page 1 of 5

Wave Life Sciences Ltd (NASDAQ:WVE): Peter Kolchinsky’s RA Capital Management filed an amended 13D.

You can check out RA Capital Management’s latest holdings and filings here.

Please follow RA Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock holdings.

Follow Peter Kolchinsky's RA Capital Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
RA Capital Management 0 7,512,049 0 7,512,049 7,512,049 27.0%
Peter Kolchinsky 0 7,512,049 0 7,512,049 7,512,049 27.0%

Follow Peter Kolchinsky's RA Capital Management

Page 1 of 5 – SEC Filing



Washington, D.C. 20549




OMB Number: 3235-0145

Expires: February 28, 2009

Estimated average burden

hours per response… 10.4



Under the Securities Exchange Act of

(Amendment No. 1)*

Wave Life
Sciences Ltd.

(Name of Issuer)


(Title of Class of Securities)


(CUSIP Number)

RA Capital Management, LLC

20 Park Plaza, Suite 1200

Boston, MA 02116

Telephone: 617.778.2512

Peter Kolchinsky

(Name, Address and Telephone Number of Person
Authorized to
Receive Notices and Communications)

13, 2017

(Date of Event Which Requires Filing of
this Statement)

If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. [ ]

Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to
be sent.

* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Wave Life Sciences Ltd.

Page 1 of 5